盛弘股份(300693.SZ):2022年度淨利預增71.88%-115.95%
格隆匯1月9日丨盛弘股份(300693.SZ)公佈2022年度業績預吿,報吿期公司歸屬於上市公司股東的淨利潤盈利1.95億元–2.45億元,比上年同期增長71.88%-115.95%;扣除非經常損益後的淨利潤盈利1.84億元–2.34億元,比上年同期增長:82.62%-132.24%;基本每股收益盈利0.95元/股-1.19元/股。
報吿期內,公司各事業部按照公司年度戰略規劃積極推進相關工作,各產品線收入均較上年有所增長,帶動公司2022年整體收入及業績較上年度大幅增長。公司2022年1-12月,預計非經常性損益對公司淨利潤的影響金額約為1100萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.